← Latest papers
🏥 surgery

Stage-specific overall survival with complete five-year follow-up after D2 gastrectomy for gastric cancer at a referral hospital in Shanghai, China: a reference for comparing hospitals

This study provides unadjusted, stage-specific five-year overall survival data from a consecutive cohort of 690 patients undergoing D2 gastrectomy for gastric cancer at a Shanghai referral hospital, serving as a reproducible reference for inter-hospital comparisons based on a proposed 16-item minimal dataset.

Original authors: Sah, B. K., Gu, D., Li, J., Chen, E.

Published 2026-10-14
📖 5 min read🧠 Deep dive

Original authors: Sah, B. K., Gu, D., Li, J., Chen, E.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Gastric cancer, often called stomach cancer, remains one of the most common and deadly diseases worldwide. When the disease is caught early enough to be removed surgically, the goal is a cure, but the chances of long-term survival depend heavily on how far the cancer has spread inside the body at the time of the operation. Doctors use a system called TNM staging to describe this spread, measuring the depth of the tumor, the number of nearby lymph nodes involved, and whether the cancer has traveled to distant organs. This classification is the single most important factor in predicting a patient's future. Because outcomes vary so much depending on this stage, comparing the performance of different hospitals is difficult. If one hospital treats mostly early-stage cases and another treats mostly advanced cases, a simple comparison of overall survival rates would be misleading. To make a fair comparison, medical leaders need a common reference point that looks at patients with the exact same stage of disease, allowing them to see if one hospital is truly doing better than another at the same level of difficulty.

Researchers at Ruijin Hospital in Shanghai set out to create such a reference point by studying a large group of patients who underwent a specific, high-quality surgery for stomach cancer. They focused on 690 consecutive patients treated in 2019, all of whom received a procedure called a D2 gastrectomy. This operation involves removing the stomach and a specific, extensive network of lymph nodes to ensure the cancer is cleared as thoroughly as possible. The team followed every single survivor for at least five years, ensuring no one was lost to the study, which is a rare level of completeness in medical research. They separated the patients into two groups: those who went straight to surgery and those who received chemotherapy before the operation. By tracking who lived and who passed away over the full five-year period, they calculated the survival rates for each stage of the disease without adjusting for other factors like age or other illnesses.

The results paint a clear picture of how the stage of the cancer dictates the outcome. For patients with the earliest stage of disease who went straight to surgery, the five-year survival rate was 95.0 percent, meaning nearly all of them were still alive five years later. As the stage became more advanced, the numbers dropped predictably. For those with stage II disease, the five-year survival rate was 83.8 percent, and for those with stage III, it fell to 56.5 percent. The researchers also looked at the specific sub-stages, finding that survival decreased steadily as the disease progressed from stage IA all the way to stage IIIC, where the five-year survival rate was 26.7 percent. For the patients who received chemotherapy before their surgery, the survival rates were lower at every corresponding stage, reflecting the fact that these patients typically had more aggressive or advanced disease to begin with. When the researchers combined the data from both groups, the overall survival for stage III patients dropped slightly to 50.2 percent, showing how mixing different treatment histories can change the statistics.

Beyond the survival numbers, the study addressed a practical problem: how can other hospitals produce these same numbers to compare themselves? The authors proposed a minimal list of sixteen data points that any hospital could collect to generate a fair comparison. Most of these items, such as the patient's age, the type of surgery performed, the stage of the cancer, and whether the patient is alive or dead, are already recorded during routine care. The list also includes the date of the last contact with the patient to ensure the five-year mark is met. The researchers emphasize that these figures are not a target that every hospital must hit, nor are they a minimum standard of care. Instead, they serve as a transparent benchmark derived from a single, high-volume center where experienced surgeons performed the operations. The goal is to allow hospitals to see where they stand relative to this reference for each specific stage of cancer, helping to identify areas for improvement without the confusion of complex statistical adjustments.

The study also highlighted the importance of complete follow-up. In many medical studies, patients are lost to tracking before five years pass, which can skew the results. In this research, every survivor was accounted for, with the last contact occurring at least 68.1 months after surgery for everyone still alive. This completeness gives the survival rates a high degree of reliability. The authors noted that while their data comes from one hospital in China, the method of reporting is designed to be universal. By providing the exact number of patients and deaths for each stage, they allow other institutions to see the raw data behind the percentages. This transparency helps doctors, hospital managers, and regulators understand that differences in survival rates might reflect differences in patient mix or data quality rather than the quality of care itself. Ultimately, the work provides a solid, unadjusted foundation for comparing how well different hospitals are treating stomach cancer, one stage at a time.

Drowning in papers in your field?

Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.

Try Digest →